Peptide Screening Strategies for Oncology Target Discovery

The search for effective oncology therapeutics increasingly relies on peptide-based molecules due to their ability to modulate complex and challenging targets. Peptides offer unique advantages in cancer research, including high specificity, structural adaptability, and the ability to target protein–protein interactions often inaccessible to small molecules. Successful discovery of oncology peptides depends on strategic screening approaches that combine library diversity, structural constraints, and high-throughput technologies.

Designing Libraries for Oncology Targets

Effective peptide screening begins with the construction of a diverse, 3D-structured library. Key considerations include:

• Linear, cyclic, and bicyclic peptides to explore multiple conformations

• Incorporation of natural and non-natural amino acids to improve binding and stability

• Trillions of variants to maximize coverage of potential interaction motifs

This diversity ensures the library can target tumor-associated proteins, including receptors, enzymes, and intracellular signaling proteins that play critical roles in cancer progression.

High-Throughput Screening for Hits

High-throughput screening (HTS) is central to identifying peptide hits from massive libraries. Oncology targets often present complex surfaces or dynamic binding sites, necessitating:

• Solution-phase or immobilized target assays to capture various binding modes

• Fluorescent, luminescent, or label-free detection methods for rapid assessment

• Automated platforms capable of testing millions to billions of sequences efficiently

The goal is to identify peptides with strong affinity, high specificity, and functional relevance to cancer pathways.

Hit Validation and Optimization

Initial hits from HTS undergo rigorous secondary validation to confirm binding and biological activity. Optimization focuses on:

• Enhancing stability and protease resistance through cyclic or bicyclic scaffolds

• Fine-tuning target selectivity to minimize off-target effects

• Adjusting physicochemical properties to improve bioavailability and pharmacokinetics

This step is critical for translating hits into viable oncology leads.

Targeting Difficult Cancer Proteins

Many cancer targets, such as oncogenic transcription factors, protein–protein interactions, or intracellular kinases, are challenging to drug with traditional small molecules. Structurally diverse peptides are uniquely suited for these targets because they:

• Access flat or shallow binding interfaces

• Maintain conformational integrity under physiological conditions

• Offer modularity for conjugation with drug delivery systems or imaging agents

Conclusion

Peptide screening strategies for oncology rely on a combination of library diversity, high-throughput screening, and structural optimization. By leveraging linear, cyclic, and bicyclic peptides enriched with natural and non-natural amino acids, researchers can efficiently discover high-affinity, selective hits against cancer-relevant targets. This approach accelerates the development of next-generation oncology therapeutics and opens pathways to previously “undruggable” targets.